With the advent of insulin 80 years ago, the management of diabetes has been revolutionized and is considered as the most outstanding achievements in the medical field in 20th century. Since then, there has been an ever –increasing awareness and acceptance of the need to achieve and Sustain near –normoglycemia to delay onset and retard the progression of diabetic angiopathy. Initially, the animal pancreas was the only source from which insulin could be produced in sufficient quantities to cope with therapeutic needs, recently even high yield beef and porcine pancreas with newer purification technology has made insulin cheaper. During the late seventies with the advancement in recombinant DNA technology, it has been possible to produce human insulin combined from alpha and beta chains expressed separately in E.coli with chemically prepared genes.
The limited pharmacology features of standard insulin, leading to hypoglycemia as glycoside hemoglobin values approach the normal range, the interest renewed to evolve safer insulin formulations that are more related to basal and meal time components of endogenous insulin ****ogues , characterized by action profiles that afford more flexible treatment regimens with a lower development of hypoglycemia.
Clinical features of rapid acting ****ogues
Injections of these rapidly acting ****ogues result in twice the maximal concentration and takes about half the time to reach the maximal concentration ,as do equivalent doses of regular insulin .peak insulin action occurs approximately twice as fast as regular insulin.
Both insulin lispro and insulin aspart are superior to regular insulin in the reduction of post prandial hyperglycemia.
In general studies have shown that rapidly acting ****ogues are superior to regular insulin for lowering glycoside hemoglobin levels in patients who receive insulin by continuous subcutaneous infusion.
The more rapid pharmodynamic effects of insulin lispro and insulin aspart make postabsortive hypoglycemia less of a problem with these ****ogues than with regular insulin.
In general studies involving multiple daily injections have demonstrated that hemoglobin rapidly acting ****ogues does not improve glycosylated hemoglobin levels .lowering of glycosylated hemoglobin levels is seen in patients who receive insulin by continuous subcutaneous infusion.
Studies have shown that as compared with a premix of 70% NPH and 30% regular insulin, the premixed ****ogues result in reduced postprandial hyperglycemia but no changes in glycosylated Levels.
AYURVEDIC HERBS TREATMENT HELPS IN MANAGEMENT OF INSULIN DEPENDENT DIABETES
Want to share with you names of herb that act specifically on INSULIN DEPENDENT DIABETES.
• NEEM patraa
• Bilav patra
• Mrigmada musk
All these herbs are collected and their extract is used in herbal medicine. This medicine is not
Only control the diabetes of high range but also a cardio protective, immunomodulator and
Antioxidant. It is also good to control the hormonal imbalance in women those who are
In menopause. Herbs activate the beta cells of pancreas.
These herbs also counteract the complication such as diabetic retinopathy ,nephropathy, neuropathy. We can use these herbal medicines in both type NIDDM 1 & 2 diabetes.
SOME points are completely medically which I want to tell you if you can understand.
These herbs do following action in our body
1. It stops the entry of glucose from the intestine level.
2. It decreases the release of glucose in blood from glycogen for\med in liver due to fat intake.
3. It exerts the mimic effect like insulin
4. It repair the B cell of the pancreas
5. It repairs the myelin sheath of the nerves to prevent diabetic neuropathy and nephropathy.
IN additive to this herbal medicine Swarn bhasam and Rajat bhasm and Vang bhasam ARE USED to control diabetes.